Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include statnews.com, Axios, WSJ and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Quick answers
Why is "Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to i" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Sanofi, Regeneron Seal Deeper Partnership Worth Up to $8 Billion bloomberg.com · 10h ago
- Sanofi, Regeneron expand partnership after Dupixent success statnews.com · 10h ago
- Sanofi, Regeneron deepen decadeslong alliance with $8B deal Axios · 10h ago
- Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal WSJ · 10h ago
- Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute Reuters · 10h ago
- Sanofi pays $1B upfront to expand immunology deal with Regeneron FirstWord PHARMA · 10h ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D Fierce Biotech · 10h ago
Topics
Related trends
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
Obesity treatment shifts focus as clinical trials test combination therapies designed to preserve lean muscle mass during weight loss.
Kodiak skyrockets on positive study data for 2 eye drugs
Kodiak stock surges after a Phase III clinical victory for its Eylea rival targeting wet AMD.
Kodiak Sciences stock soars on positive AMD trial data
Kodiak Sciences shares surged over 90% following positive Phase 3 trial results for an eye disease drug targeting AMD.
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.
Regeneron backs $75M series A for antibody upstart Infinimmune
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.